In‐vivo purging of the circulating clonal T‐cells with Alemtuzumab prior to autologous peripheral blood hematopoietic cell mobilization and transplantation
Open Access
- 13 April 2011
- journal article
- other
- Published by Wiley in British Journal of Haematology
- Vol. 154 (3) , 415-418
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemiaLeukemia, 2009
- Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter StudyJournal of Clinical Oncology, 2009
- International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical OutcomesJournal of Clinical Oncology, 2008
- Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphomaAnnals of Oncology, 2008
- Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphomaAnnals of Oncology, 2008
- Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantationLeukemia, 2006
- Alemtuzumab As Consolidation After a Response to Fludarabine Is Effective in Purging Residual Disease in Patients With Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2006
- 9-Color and 10-Color Flow Cytometry in the Clinical LaboratoryArchives of Pathology & Laboratory Medicine, 2006
- Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001Blood, 2006
- Increased Incidence of Cytomegalovirus Disease After Autologous CD34-Selected Peripheral Blood Stem Cell TransplantationBlood, 1999